CY1122009T1 - Συνθεσεις που περιλαμβανουν δεσμευτικα των χολικων οξεων για τη θεραπευτικη αντιμετωπιση οισοφαγικων διαταραχων - Google Patents
Συνθεσεις που περιλαμβανουν δεσμευτικα των χολικων οξεων για τη θεραπευτικη αντιμετωπιση οισοφαγικων διαταραχωνInfo
- Publication number
- CY1122009T1 CY1122009T1 CY20191100940T CY191100940T CY1122009T1 CY 1122009 T1 CY1122009 T1 CY 1122009T1 CY 20191100940 T CY20191100940 T CY 20191100940T CY 191100940 T CY191100940 T CY 191100940T CY 1122009 T1 CY1122009 T1 CY 1122009T1
- Authority
- CY
- Cyprus
- Prior art keywords
- bile acid
- compositions containing
- therapeutic treatment
- acid binders
- gaba
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
- 239000003613 bile acid Substances 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 abstract 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 229940069428 antacid Drugs 0.000 abstract 1
- 239000003159 antacid agent Substances 0.000 abstract 1
- 229920000080 bile acid sequestrant Polymers 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- 230000001473 noxious effect Effects 0.000 abstract 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 229940126409 proton pump inhibitor Drugs 0.000 abstract 1
- 239000000612 proton pump inhibitor Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
- C08F226/02—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Αποκαλύπτονται στο παρόν καινοτόμες συνθέσεις και μέθοδοι για τη θεραπεία ή την πρόληψη διαταραχών της άνω γαστρεντερικής οδού και για την προστασία του πολύστιβου πλακώδους επιθηλίου από βλάβη οφειλόμενη σε επιβλαβή ουσία. Οι μέθοδοι περιλαμβάνουν γενικά τη χορήγηση σε έναν ασθενή που έχει ανάγκη μιας θεραπευτικά αποτελεσματικής ποσότητας μιας φαρμακευτικής σύνθεσης που περιλαμβάνει τουλάχιστον ένα δεσμευτικό των χολικών οξέων, μόνο του ή σε συνδυασμό με τουλάχιστον έναν αναστολέα αντλίας πρωτονίων, και προαιρετικά έναν ή περισσότερους παράγοντες που επιλέγονται από αντιόξινα, ανταγωνιστές των υποδοχέων Η2 της ισταμίνης, αγωνιστές του αμινοβουτυρικού οξέος-b (GABA-B), προφάρμακα αγωνιστών GABA-B και αναστολείς πρωτεασών.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87149906P | 2006-12-22 | 2006-12-22 | |
PCT/US2007/088624 WO2008080092A2 (en) | 2006-12-22 | 2007-12-21 | Compositions comprising bile acid sequestrants for treating esophageal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1122009T1 true CY1122009T1 (el) | 2020-10-14 |
Family
ID=39277294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100940T CY1122009T1 (el) | 2006-12-22 | 2019-09-09 | Συνθεσεις που περιλαμβανουν δεσμευτικα των χολικων οξεων για τη θεραπευτικη αντιμετωπιση οισοφαγικων διαταραχων |
Country Status (19)
Country | Link |
---|---|
US (4) | US9205094B2 (el) |
EP (4) | EP3628307A1 (el) |
JP (2) | JP2010514702A (el) |
AU (1) | AU2007336731B2 (el) |
CA (1) | CA2673665C (el) |
CY (1) | CY1122009T1 (el) |
DK (1) | DK2124884T3 (el) |
ES (1) | ES2739542T3 (el) |
HU (1) | HUE046465T2 (el) |
IL (1) | IL199477A (el) |
LT (1) | LT2124884T (el) |
NZ (2) | NZ598728A (el) |
PL (1) | PL2124884T3 (el) |
PT (1) | PT2124884T (el) |
RU (3) | RU2491075C2 (el) |
SI (1) | SI2124884T1 (el) |
TR (1) | TR201910825T4 (el) |
WO (1) | WO2008080092A2 (el) |
ZA (1) | ZA200904573B (el) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200904573B (en) | 2006-12-22 | 2010-09-29 | Ironwood Pharmaceuticals Inc | Compositions comprising bile acid sequestrants for treating esophageal disorders |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
TWI605837B (zh) * | 2011-01-27 | 2017-11-21 | Kowa Co Ltd | Pharmaceutical composition containing water-insoluble drug and pharmaceutical preparation |
ITRM20120041A1 (it) * | 2012-02-08 | 2013-08-09 | Dicofarm Spa | "prodotto a base di glucomannano e chitosano utile per il trattamento del reflusso gastroesofageo" |
WO2014113377A1 (en) * | 2013-01-15 | 2014-07-24 | Ironwood Pharmaceuticals, Inc. | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
CA2952223C (en) | 2014-06-13 | 2023-08-01 | United Therapeutics Corporation | Treprostinil formulations |
TWI732337B (zh) * | 2014-06-20 | 2021-07-01 | 美商梅琳塔有限責任公司 | 醫藥組成物及其用途 |
CA3042475C (en) * | 2016-11-02 | 2024-01-16 | Novartis Ag. | Combinations of fgfr4 inhibitors and bile acid sequestrants |
RU2667651C1 (ru) * | 2017-12-26 | 2018-09-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения эрозивной формы гастроэзофагеальной рефлюксной болезни у пациентов, получающих химиотерапию |
EP3863643A4 (en) * | 2018-10-12 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | AZD3355 (LESOGABERAN) FOR THE TREATMENT AND PREVENTION OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), HEPATIC FIBROSIS AND OTHER LIVER CONDITIONS |
WO2021212022A1 (en) * | 2020-04-16 | 2021-10-21 | The Medical College Of Wisconsin, Inc. | Aerosolized formulations of hiv protease inhibitors for the treatment of airway reflux |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3624209A (en) * | 1966-12-28 | 1971-11-30 | Bristol Myers Co | Composition for treatment of gastro-intestinal disorders |
US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
SE416649B (sv) | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
DE2704425C2 (de) * | 1977-02-03 | 1982-10-07 | Interx Research Corp., 66044 Lawrence, Kan. | Verwendung von Styrol-Divinylbenzol-Copolymer-Anionenaustauscherharzen bei der Bekämpfung von Magengeschwüren |
GB1566609A (en) * | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
JPS5692217A (en) | 1979-12-26 | 1981-07-25 | Kowa Co | Easily absorbable enzyme preparation |
US4359465A (en) | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
US4472409A (en) | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
AU545463B2 (en) | 1982-06-25 | 1985-07-18 | Kowa Co. Ltd. | Benzoyl piperacine esters |
SE8300736D0 (sv) | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
JPS59222484A (ja) | 1983-06-02 | 1984-12-14 | Kowa Co | テトラヒドロナフチルカルボン酸フエニルエステル誘導体 |
JPS608225A (ja) | 1983-06-29 | 1985-01-17 | Kowa Co | 腸管吸収医薬組成物 |
IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
US4735804A (en) | 1985-05-10 | 1988-04-05 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
US4738975A (en) | 1985-07-02 | 1988-04-19 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, and use as anti-ulcer agents |
CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
US4851232A (en) | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
FI96860C (fi) | 1987-06-17 | 1996-09-10 | Eisai Co Ltd | Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi |
IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
JP2916206B2 (ja) | 1990-04-28 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ペプチド |
JP2916205B2 (ja) | 1990-04-28 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ペプチド |
DK223790D0 (da) | 1990-09-18 | 1990-09-18 | Novo Nordisk As | Proteaseholdig detergentkomposition |
US5312824A (en) | 1990-10-17 | 1994-05-17 | Takeda Chemical Industries, Ltd. | Certain 2-[(4-difluoromethoxy-2-pyridyl)-methylthio or methylsulfinyl-5-benzimidazoles useful for treating peptic ulcers |
US5167483A (en) | 1990-12-24 | 1992-12-01 | Gardiner Samuel W | Method for utilizing angular momentum in energy conversion devices and an apparatus therefore |
IT1245891B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. |
YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
US5877192A (en) | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
US5703188A (en) | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
US5670163A (en) | 1994-06-20 | 1997-09-23 | Kv Pharmaceuticals Company | Long acting GI and esophageal protectant |
CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
DE19534996A1 (de) | 1995-09-21 | 1997-03-27 | Bosch Gmbh Robert | Verfahren zur Verbrennungsaussetzererkennung durch Auswertung von Drehzahlschwankungen |
SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US6423754B1 (en) | 1997-06-18 | 2002-07-23 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with polyallylamine polymers |
PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
US20040062802A1 (en) | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
DE19850309A1 (de) | 1998-10-30 | 2000-05-04 | Lohmann Therapie Syst Lts | Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
US6881420B2 (en) | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
US6638498B2 (en) | 2000-06-30 | 2003-10-28 | Semorex Inc. | Molecularly imprinted polymers for the treatment and diagnosis of medical conditions |
WO2002009815A2 (en) * | 2000-07-28 | 2002-02-07 | F. Hoffmann-La Roche Ag | New pharmaceutical composition |
AU2001289696B2 (en) | 2000-07-28 | 2006-07-06 | Cheplapharm Arzneimittel Gmbh | New use of lipase inhibitors |
US20030031711A1 (en) | 2001-05-29 | 2003-02-13 | Fara John W. | Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough |
KR20040018394A (ko) * | 2001-07-04 | 2004-03-03 | 썬 파마슈티컬 인더스트리스 리미티드 | 위 정체 제어되는 약물 전달 계 |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
CN1638741A (zh) | 2002-01-03 | 2005-07-13 | 史密丝克莱恩比彻姆公司 | 新药物剂型及生产这种剂型的方法 |
CN1642556A (zh) * | 2002-03-18 | 2005-07-20 | 法玛西雅公司 | 醛固酮受体拮抗剂与胆汁酸多价螯合剂的联合 |
GB0209481D0 (en) * | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
EP1524963A2 (en) | 2002-06-26 | 2005-04-27 | Cadila Healthcare Ltd. | Novel floating dosage form |
US20040043072A1 (en) * | 2002-09-04 | 2004-03-04 | Will Joanne Patricia | Alleviation of upper gastrointestinal irritation |
KR20050083750A (ko) | 2002-10-11 | 2005-08-26 | 디포메드 디벨롭먼트 리미티드 | 위-체류성 레보도파 전달 형태 |
US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
ATE428411T1 (de) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | Hdl-verstärkende kombinationstherapie-komplexe |
US20070196396A1 (en) | 2004-02-11 | 2007-08-23 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
EP2335709A1 (en) * | 2004-03-26 | 2011-06-22 | Mitsubishi Tanabe Pharma Corporation | Insulin resistance improving agent |
FR2874325B1 (fr) | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
US20060073213A1 (en) | 2004-09-15 | 2006-04-06 | Hotamisligil Gokhan S | Reducing ER stress in the treatment of obesity and diabetes |
US20070292523A1 (en) | 2004-09-27 | 2007-12-20 | Joey Moodley | Dihydropyrimidine Formulations |
US20080153779A1 (en) * | 2005-02-01 | 2008-06-26 | Jun Liao | Gastric Retention and Controlled Release Delivery System |
KR100822519B1 (ko) | 2005-02-15 | 2008-04-16 | 주식회사종근당 | 위장 내에서 제어방출되는 단일 매트릭스 정제 |
EP1877067A1 (en) * | 2005-04-26 | 2008-01-16 | Microbia, Inc. | 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia |
US20070269512A1 (en) | 2006-05-22 | 2007-11-22 | Wang Wenhua W | Gastroretentive sustained release formulations |
CA2661404A1 (en) | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
ZA200904573B (en) | 2006-12-22 | 2010-09-29 | Ironwood Pharmaceuticals Inc | Compositions comprising bile acid sequestrants for treating esophageal disorders |
US20110129433A1 (en) | 2008-06-26 | 2011-06-02 | Ironwood Pharmaceuticals, Inc. | Compositions and Methods for Treating or Preventing Gastrointestinal Disorders and GERD-Related Respiratory Disorders |
-
2007
- 2007-12-21 ZA ZA200904573A patent/ZA200904573B/xx unknown
- 2007-12-21 CA CA2673665A patent/CA2673665C/en active Active
- 2007-12-21 ES ES07869791T patent/ES2739542T3/es active Active
- 2007-12-21 LT LTEP07869791.9T patent/LT2124884T/lt unknown
- 2007-12-21 PL PL07869791T patent/PL2124884T3/pl unknown
- 2007-12-21 TR TR2019/10825T patent/TR201910825T4/tr unknown
- 2007-12-21 EP EP19185001.5A patent/EP3628307A1/en not_active Withdrawn
- 2007-12-21 SI SI200732121T patent/SI2124884T1/sl unknown
- 2007-12-21 PT PT07869791T patent/PT2124884T/pt unknown
- 2007-12-21 EP EP12164341A patent/EP2478895A3/en not_active Withdrawn
- 2007-12-21 WO PCT/US2007/088624 patent/WO2008080092A2/en active Application Filing
- 2007-12-21 AU AU2007336731A patent/AU2007336731B2/en not_active Ceased
- 2007-12-21 EP EP07869791.9A patent/EP2124884B1/en active Active
- 2007-12-21 HU HUE07869791A patent/HUE046465T2/hu unknown
- 2007-12-21 DK DK07869791.9T patent/DK2124884T3/da active
- 2007-12-21 EP EP12164340A patent/EP2478894A3/en not_active Withdrawn
- 2007-12-21 RU RU2009128202/15A patent/RU2491075C2/ru active
- 2007-12-21 NZ NZ598728A patent/NZ598728A/xx unknown
- 2007-12-21 NZ NZ578204A patent/NZ578204A/en unknown
- 2007-12-21 JP JP2009543271A patent/JP2010514702A/ja active Pending
- 2007-12-21 US US12/520,748 patent/US9205094B2/en active Active
-
2009
- 2009-06-21 IL IL199477A patent/IL199477A/en active IP Right Grant
-
2013
- 2013-04-17 RU RU2013117758A patent/RU2705364C2/ru active
-
2015
- 2015-01-30 JP JP2015016788A patent/JP6141891B2/ja not_active Expired - Fee Related
- 2015-11-03 US US14/931,215 patent/US20160051577A1/en not_active Abandoned
-
2016
- 2016-12-19 US US15/383,056 patent/US20170290767A1/en not_active Abandoned
-
2017
- 2017-11-15 US US15/813,850 patent/US20180235878A1/en not_active Abandoned
-
2019
- 2019-09-09 CY CY20191100940T patent/CY1122009T1/el unknown
- 2019-10-25 RU RU2019134181A patent/RU2019134181A/ru unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122009T1 (el) | Συνθεσεις που περιλαμβανουν δεσμευτικα των χολικων οξεων για τη θεραπευτικη αντιμετωπιση οισοφαγικων διαταραχων | |
CY1122134T1 (el) | Συνθεση για χρηση στη θεραπευτικη αντιμετωπιση της γαστρεντερικης δυσκινησιας | |
CY1121853T1 (el) | Συνδυαστικη θεραπεια για την αγωγη του διαβητη | |
WO2009158625A3 (en) | Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders | |
CY1118672T1 (el) | Συνθεσεις ταπενταδολης | |
PE20081187A1 (es) | Combinaciones de inhibidores de ang2 y vegf | |
CY1112751T1 (el) | Μεθοδος διαμορφωσης του συζευγμενου με πρωτεϊνη g υποδοχεα gpr119 και επιλεγμενες ενωσεις | |
EA201591338A1 (ru) | Гастроретентивная лекарственная форма секвестранта желчных кислот с замедленным высвобождением для перорального применения | |
SE0203065D0 (sv) | Gastric acid secretion inhibiting composition | |
ECSP066950A (es) | Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2 | |
ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
TR201907874T4 (tr) | Düşük sülfat fukanlar kullanarak fibröz yapışmaları ya da inflamatuar hastalıkları inhibe etmeye yönelik farmasötik kompozisyonlar ve yöntemler. | |
NO20083885L (no) | Fremgangsmate for behandling av inflammatoriske sykdommer | |
CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
NO20065271L (no) | Sammensetninger innbefattende alfa-2-delta ligander | |
DK2012763T3 (da) | Farmaceutisk kombination omfattende 3-(3-dimethylamono-1-ethyl-2-methyl-propyl) phenol og et NSAID | |
CY1107945T1 (el) | Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β | |
CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
DK2012764T3 (da) | Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol | |
WO2008117268A3 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
CY1114791T1 (el) | Πιμοβενδανη για χρηση στη θεραπεια της υπερτροφικης μυοκαρδιοπαθειας σε γατες | |
CY1114266T1 (el) | Ανταγωνιστης υποδοχεα της αγγειοτενσινης ιι για τη θεραπευτικη αγωγη συστημικων νοσων σε γατες | |
ATE458746T1 (de) | Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs | |
CY1119819T1 (el) | Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας |